The KRAS oncoprotein possesses a unique molecular structure that potentiates it as a driver of multiple cancer cell hallmarks (including proliferation, migration, metastasis, angiogenesis, inflammation, and apoptosis evasion), but also renders it non-actionable due to the absence of a druggable deep pocket [2,3]. Here, KRAS is linked to cancer.